-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tumor is a complex and highly heterogeneic disease, the pathogenesis is not completely clear.
rapidly growing accumulation of big tumor data, such as genomic and transcriptional data, provides an excellent opportunity to identify new tumor-related genes and gain an in-depth understanding of the molecular mechanisms of tumor development.
The Kong Qingpeng team at the Kunming Institute of Zoology of the Chinese Academy of Sciences found that the ERCC6L gene was consistently and significantly higher in 12 tumors by analyzing transcriptional data from 12 tumors from the TCGA database.
the gene is a newly discovered DNA lysogene that is closely related to embryonic development, but the relationship with tumors has never been reported.
researchers first found in in-body cell experiments that silence ERCC6L significantly inhibited the proliferation of breast cancer cells (MCF-7, MDA-MB-231) and kidney cancer cells (786-0), with cell cycles blocked in stage G0/G1.
further analysis of ERCC6L knock-down cell transcription group data and verification experiments found that: ERCC6L knock-down can significantly inhibit the RAB31 gene transcription and translation levels, while reducing the MAPK pathway downstream of RAB31 phosphorylation level and CDK2 protein expression.
in order to verify the results of in-body experiments, the team conducted a naked mouse tumor experiment, the results showed that silence ERCC6L can be inoculated on the seventh day after the tumor cells began to significantly inhibit tumor growth.
Not only that, the expression level of ERCC6L is highly related to the tumor stage of the patient, and the high expression of ERCC6L can indicate the low survival rate of tumor patients, suggesting that ERCC6L is a good marker of tumor prognostication, but also a potential target for tumor treatment and drug development.
the findings were recently published in the journal Oncotarget.
Shaoyan, a member of the project team, and Yu Qin, a doctoral student, are co-authors of the article, and researcher Kong Qingpeng and associate researcher He Yong han are side-by-side correspondents of the article.
project has been supported by the Ministry of Science and Technology '973' project, the National Natural Science Foundation of China and the Chinese Academy of Sciences and other research fund projects.
.